Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

September 22, 2020

Canadian Students Receive $90,000 in Support from Bayer Fund’s Opportunity Scholarship

Read more
September 01, 2020

Bayer launches Proline® GOLD for premium protection against sclerotinia in canola

Read more
August 14, 2020

Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.

• Further expansion of Bayer’s drug development pipeline in Women’s Healthcare • Innovative non-hormonal oral compound NT-814 being studied to alleviate menopausal symptoms • Development compound recently completed Phase IIb • Reinforces Bayer’s position in Women’s Healthcare Read more
August 04, 2020

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

• Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care • Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events • Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized • Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes Read more
July 23, 2020

Bayer Inc. launches FastTRK, a complimentary clinical testing program for the diagnosis of NTRK gene fusions in TRK fusion cancer patients in Canada

Read more
June 24, 2020

Bayer announces agreements to resolve major legacy Monsanto litigation

Company will make a total payment of $10.1 billion to $10.9 billion (€9.1 billion to €9.8 billion) to resolve current and address potential future Roundup™ litigation/ • Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million/ • Funding sourced from free cash flow and Animal Health divestment /• Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs Read more
June 17, 2020

Non-metastatic castration resistant prostate cancer treatment NUBEQA® (darolutamide) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer

Read more
April 21, 2020

Bayer partners with Population Health Research Institute (PHRI) on major global research study on COVID-19 treatments

Read more
March 26, 2020

Bayer Scholarships for Students Now Accepting Applications for 2020

Over $125,000 in scholarships available to Canadian students across two programs/ • Canadian agriculture needs bright minds across many disciplines/ • Application deadlines in April and June Read more
February 27, 2020

ALTAIR study published confirming efficacy of EYLEA® treat and extend dosing regimens for patients with wet AMD

Read more